COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2020 and March 31, 2019 is as follows (in thousands):



Three Months Ended March 31, 2020	Contingent Consideration Liability Related to Acquisition of Arkis (See Note 2)			Contingent Consideration Liability Related to Acquisition of Derma Sciences		Location in Financial Statements
	Long-term			Long-term
Balance as of January 1, 2020	$	14,210		$	230
Payments	—			—
Loss from change in fair value of contingent consideration liabilities	(1,051		)	—		Research and development
Balance as of March 31, 2020	$	13,159		$	230



Three Months Ended March 31, 2019	Contingent Consideration Liability Related to Acquisition of Derma Sciences		Location in Financial Statements
	Long-term
Balance as of January 1, 2019	$	230
Payments	—
Loss from change in fair value of contingent consideration liabilities	—		Research and development
Balance as of March 31, 2019	$	230